leisure time -WSS

leisure time

author：focus 2025-09-29 01:37:58 - browse：4

AstraZeneca said Friday it will buy up a group of early-stage gene therapies from Pfizer, bucking a trend of drugmakers axing programs and exiting a field that had once captured the imagination — and checkbooks — of many pharmaceutical executives.

AstraZeneca will pay Pfizer up to $1 billion plus royalties for the portfolio of treatments, none of which has entered clinical trials yet. The companies did not say how much it is paying upfront.

The moves come six months after Pfizer said it would stop much of its work on early-stage gene therapy programs, in which researchers try to deliver replacement genes encased in small, non-pathogenic bugs called adeno-associated viruses, or AAVs. Instead, it would focus on newer technologies, such as gene editing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： How the political right came to back psychedelics to treat trauma

explore

Wikipedia

WSS

The explosion of genetic testing requires a new approach

Impact of Dobbs ruling felt at reproductive medicine meeting

Palantir health business leans on meeting customers’ needs

FDA warns J&J's Abiomed: We will regulate your software

Will Ozempic

Senate committee scrutinizes Medicare Advantage brokers

focus

leisure time

explore

Alkermes shareholders re

FDA gives detailed accounting of AI

As demand for Covid shots wanes, Moderna seeks its next success

Why 40% Americans with Parkinson’s don’t see a neurologist

At least 13 dead in Texas as scorching temps continue

HHS leader on health, climate change and biopharma emissions

Drug repurposing or repositioning? The language matters

Iowa House, Senate pass 6

Virginia high school admissions case could be legal follow

Hospital price transparency does save money, advocate argues

hotspot

Studies point to risks of excluding people with obesity from drug trials

Why 40% Americans with Parkinson’s don’t see a neurologist

Impact of Dobbs ruling felt at reproductive medicine meeting

The explosion of genetic testing requires a new approach

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

HHS leader on health, climate change and biopharma emissions

hotspot

Wikipedia

leisure time

leisure time